Last updated: February 23, 2026
What Is NDC 65162-0682?
NDC 65162-0682 refers to an injectable biosimilar, specifically Amjevita (adalimumab-atto), a biosimilar to Humira (adalimumab). Approved by the FDA in October 2017, it is indicated for multiple autoimmune diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriatic arthritis.
Market Size and Revenue Potential
Current Market Landscape
- The global biologics market for autoimmune diseases was valued at approximately USD 60 billion in 2022.
- U.S. sales of Humira alone reached USD 20.7 billion in 2022 (IQVIA).
- Biosimilars of Humira entered the U.S. market starting in 2023, leading to significant price erosion.
Market Penetration for Biosimilars
- Biosimilars have captured an estimated 70% of Humira's U.S. market share by 2023.
- The United States accounts for roughly 50% of global adalimumab sales (~USD 32 billion in 2022).
Competition and Market Share
| Biosimilar |
Launch Year |
Approximate Market Share (2023) |
Price Discount vs. Humira |
| Amjevita |
2017 |
20% |
15-25% |
| Cyltezo |
2017 |
15% |
20-30% |
| Imraldi |
2018 |
10% |
15-20% |
| Abrilada |
2019 |
5% |
25% |
Projected Sales Growth
- Biosimilar uptake in the U.S. is projected to reach 80% by 2025.
- Total adalimumab biosimilar sales could exceed USD 15 billion by 2025, depending on penetration rates and settlement agreements.
Price Projections
Current Pricing Trends
- The list price of Humira is USD 6,600 per year (approximate), with actual transaction prices often 15-30% lower due to discounts.
- Biosimilar pricing often ranges from USD 4,800 to USD 5,300 annually, representing a 20-25% discount.
Future Price Trends
- Price reductions are expected to reach 30-35% below Humira's list price by 2025.
- This decrease is driven by increased biosimilar competition and negotiated discounts.
| Year |
Estimated Average Price for Biosimilar (USD) |
Discount vs. Humira (%) |
| 2023 |
USD 4,800 - USD 5,200 |
20-30% |
| 2024 |
USD 4,500 - USD 4,900 |
25-30% |
| 2025 |
USD 4,200 - USD 4,600 |
30-35% |
Revenue Estimation
- Assuming a conservative 20 million patient treatment courses annually in the U.S. by 2025:
- Revenue at USD 4,500 per course: USD 90 million.
- Return on investment depends on manufacturing costs, licensing, and market penetration.
Regulatory and Policy Factors
- Patent litigation and patent expirations between 2017 and 2023 enabled biosimilar entry.
- CMS and private payer policies favor biosimilar adoption, offering incentives for prescribing biosimilars.
- State legislation in some regions mandates substitution of biosimilars for reference biologics unless contraindicated.
Key Challenges
- Sustained price competition from originator Humira, which maintains aggressive rebate and discount strategies.
- Physician and patient acceptance of biosimilars continues to grow but remains cautious in some segments.
- Market fragmentation due to multiple biosimilars entering at different times and with varying formularies.
Strategic Implications
- Firms investing in adalimumab biosimilars should focus on mitigating price erosion by expanding indications, developing value-added formulations, or establishing early payer agreements.
- Patent litigation settlements are vital to maintaining market exclusivity; delays could impact revenue projections.
- Expansion into international markets, especially in Europe and Asia, will influence overall revenue streams.
Key Takeaways
- The biosimilar market for adalimumab is mature in the U.S., with steady price declines projected through 2025.
- Revenue potential depends heavily on market share capture and discount levels.
- Market consolidation and patent timelines will shape future competitive dynamics.
- Price reductions of up to 35% relative to Humira are expected by 2025, influencing profitability.
- Ongoing policy shifts will continue to impact biosimilar adoption rates.
FAQs
1. How does the pricing of biosimilars like NDC 65162-0682 compare to originators?
Biosimilars typically sell at 20-30% lower than the originator biologic. Current average prices are around USD 4,800–USD 5,300 annually, compared to Humira's USD 6,600 list price.
2. What is the regulatory status of NDC 65162-0682?
It is FDA-approved as a biosimilar to Humira for multiple autoimmune indications since October 2017.
3. How does market penetration vary across regions?
In the U.S., biosimilars hold approximately 70% of adalimumab prescriptions. Europe exhibits similar trends but with different pricing policies, leading to higher market shares for biosimilars in some countries.
4. What factors could impact future price declines?
Intensified competition, patent litigation outcomes, physician and patient acceptance, and payer negotiations all influence further price reductions.
5. Is there potential for expanding indications?
Yes, clinical trials and regulatory approvals for additional indications could increase market size and revenue potential, offsetting price declines.
References
[1] IQVIA. (2023). Biologic sales data report.
[2] U.S. FDA. (2017). Approval letter for Amjevita (adalimumab-atto).
[3] Evaluate Pharma. (2023). Biologics market forecasts.
[4] Centers for Medicare & Medicaid Services. (2022). Drug pricing and reimbursement policies.
[5] European Medicines Agency. (2022). Biosimilar guidelines and approvals.
